Chronic kidney disease (CKD) in the elderly – a geriatrician's perspective

References

• Schoolwerth A C, Engelgau M M, Hostetter T H, Rufo K H, Chianchiano D, McClellan W M, et al. Chronic kidney disease: a public health problem that needs a public health action plan. Prev Chronic Dis 2006; 3: A57
   PubMedGoogle Scholar
• US Renal Data System. USRDS 2004 annual data report. Atlas of end-stage renal disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, http://www.usrds.org/atlas_2004.htm. Accessed 20.7.2006
   Google Scholar
• Coresh J, Astor B C, Greene T, Eknoyan G, Levey A S. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 2003; 41: 1–12
   PubMed Web of Science ®Google Scholar
• US Renal Data System: USRDS 2003 annual data report: atlas of end stage renal disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney diseases, Bethesda, MD 2003
   Google Scholar
• Xue J L, Ma J Z, Louis T A, Collins A J. Forecast of the number of patients with end-stage renal disease in the United States to the year 2010. J Am Soc Nephrol 2001; 12: 2753–2758
   PubMed Web of Science ®Google Scholar
• Hansberry M R, Whittier W L, Krause M W. The elderly patient with chronic kidney disease. Adv Chronic Kidney Dis 2005; 12: 71–77
   PubMed Web of Science ®Google Scholar
• Lamb E J, O'Riordan S E, Delaney M P. Kidney function in older people: pathology, assessment and management. Clin Chim Acta 2003; 334: 25–40
   PubMed Web of Science ®Google Scholar
• John R, Webb M, Young A, Stevens P E. Unreferred chronic kidney disease: a longitudinal study. Am J Kidney Dis 2004; 43: 825–835
   PubMed Web of Science ®Google Scholar
• Chapter 1. Chronic kidney disease. US Renal Data System: USRDS 2006 Annual Data Report: atlas of end stage renal disease in the United States. National Institute of Health, National Institute of Diabetes & Digestive Kidney Diseases, Bathesda, MD 2006; 47–64, Accessed at: http://www.usrds.org/2006/pdf/01_ckd_06.pdf. Accessed 24.12.2006
   Google Scholar
• Taal M W, Brenner B M. Predicting initiation and progression of chronic kidney disease: developing renal risk scores. Kidney Int 2006; 70: 1694–1705
   PubMed Web of Science ®Google Scholar
• Iseki K, Iseki C, Ikemiya Y, Fukiyama K. Risk of developing end-stage renal disease in a cohort of mass screening. Kidney Int 1996; 49: 800–805
   PubMed Web of Science ®Google Scholar
• Weller J M, Wu S C, Ferguson C W, Hawthorne V M. End-stage renal disease in Michigan. Incidence, underlying causes, prevalence, and modalities of treatment. Am J Nephrol 1985; 5: 84–95
   PubMed Web of Science ®Google Scholar
• Haroun M K, Jaar B G, Hoffman S C, Comstock G W, Klag M J, Coresh J. Risk factors for chronic kidney disease: a prospective study of 23,534 men and women in Washington County, Maryland. J Am Soc Nephrol. 2003; 14: 2934–2941
   PubMed Web of Science ®Google Scholar
• Silbiger S R, Neugarten J. The role of gender in the progression of renal disease. Adv Ren Replace Ther 2003; 10: 3–14
   PubMedGoogle Scholar
• Gandolfo M T, Verzola D, Salvatore F, Gianiorio G, Procopio V, Romagnoli A, et al. Gender and the progression of chronic renal diseases: does apoptosis make the difference?. Minerva Urol Nefrol 2004; 56: 1–14
   PubMedGoogle Scholar
• Seliger S L, Davis C, Stehman-Breen C. Gender and the progression of renal disease. Curr Opin Nephrol Hypertens 2001; 10: 219–225
   PubMed Web of Science ®Google Scholar
• Morley J E, Haren M T, Rolland Y, Kim M J. Frailty. Med Clin North Am 2006; 90: 837–847
   PubMed Web of Science ®Google Scholar
• Fried L P, Tangen C M, Walston J, Newman A B, Hirsch C, Gottdiener J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci 2001; 56: M146–M156
   PubMed Web of Science ®Google Scholar
• Fried L P, Ferrucci L, Darer J, Williamson J D, Anderson G. Untangling the concepts of disability, frailty, and comorbidity: implications for improved targeting and care. J Gerontol A Biol Sci Med Sci 2004; 59: 255–263
   PubMed Web of Science ®Google Scholar
• Walston J, Fried L P. Frailty and the older man. Med Clin North Am 1999; 83: 1173–1194
   PubMed Web of Science ®Google Scholar
• Fried L P, Newman A, Walston J, et al. Frailty and mortality in the cardiovascular health study. Report presented at 51st Annual Scientific Meeting of the Gerontological Society of America, Philadelphia, November, 1998
   Google Scholar
• Newman A, Walston J, Hirsch C, et al. Physiologic correlates of frailty in the cardiovascular health study cohort. Report presented at 51st Annual Scientific Meeting of the Gerontological Society of America, Philadelphia, November, 1998
   Google Scholar
• Morley J E, Kaiser F E, Sih R, Hajjar R, Perry H M, III. Testosterone and frailty. Clin Geriatr Med 1997; 13: 685–695
   PubMed Web of Science ®Google Scholar
• Phillips S K, Rook K M, Siddle N C, Bruce S A, Woledge R C. Muscle weakness in women occurs at an earlier age than in men, but strength is preserved by hormone replacement therapy. Clin Sci (Lond) 1993; 84: 95–98
   PubMed Web of Science ®Google Scholar
• Morley J E, Perry H M, III, Kaiser F E, Kraenzle D, Jensen J, Houston K, et al. Effects of testosterone replacement therapy in old hypogonadal males: a preliminary study. J Am Geriatr Soc 1993; 41: 149–152
   PubMed Web of Science ®Google Scholar
• Reid I R, Wattie D J, Evans M C, Stapleton J P. Testosterone therapy in glucocorticoid-treated men. Arch Intern Med 1996; 156: 1173–1177
   PubMed Web of Science ®Google Scholar
• Sih R, Morley J E, Kaiser F E, Perry H M, III, Patrick P, Ross C. Testosterone replacement in older hypogonadal men: a 12-month randomized controlled trial. J Clin Endocrinol Metab 1997; 82: 1661–1667
   PubMed Web of Science ®Google Scholar
• Tenover J S. Effects of testosterone supplementation in the aging male. J Clin Endocrinol Metab 1992; 75: 1092–1098
   PubMed Web of Science ®Google Scholar
• Urban R J, Bodenburg Y H, Gilkison C, Foxworth J, Coggan A R, Wolfe R R, et al. Testosterone administration to elderly men increases skeletal muscle strength and protein synthesis. Am J Physiol 1995; 269: E820–E826
   PubMed Web of Science ®Google Scholar
• Morley J E. An overview of diabetes mellitus in older persons. Clin Geriatr Med 1999; 15: 211–224
   PubMed Web of Science ®Google Scholar
• Rodriguez-Saldana J, Morley J E, Reynoso M T, Medina C A, Salazar P, Cruz E, et al. Diabetes mellitus in a subgroup of older Mexicans: prevalence, association with cardiovascular risk factors, functional and cognitive impairment, and mortality. J Am Geriatr Soc 2002; 50: 111–116
   PubMed Web of Science ®Google Scholar
• Miller D K, Lui L Y, Perry H M, III, Kaiser F E, Morley J E. Reported and measured physical functioning in older inner-city diabetic African Americans. J Gerontol A Biol Sci Med Sci 1999; 54: M230–M236
   Web of Science ®Google Scholar
• Shlipak M G, Stehman-Breen C, Fried L F, Song X, Siscovick D, Fried L P, et al. The presence of frailty in elderly persons with chronic renal insufficiency. Am J Kidney Dis 2004; 43: 861–867
   PubMed Web of Science ®Google Scholar
• McIntyre C W, Selby N M, Sigrist M, Pearce L E, Mercer T H, Naish P F. Patients receiving maintenance dialysis have more severe functionally significant skeletal muscle wasting than patients with dialysis-independent chronic kidney disease. Nephrol Dial Transplant 2006; 21: 2210–2216
   PubMed Web of Science ®Google Scholar
• Kovesdy C P, Trivedi B K, Anderson J E. Association of kidney function with mortality in patients with chronic kidney disease not yet on dialysis: a historical prospective cohort study. Adv Chronic Kidney Dis 2006; 13: 183–188
   PubMed Web of Science ®Google Scholar
• Tonelli M, Wiebe N, Culleton B, House A, Rabbat C, Fok M, et al. Chronic kidney disease and mortality risk: a systematic review. J Am Soc Nephrol 2006; 17: 2034–2047
   PubMed Web of Science ®Google Scholar
• K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39: S1–S266
   PubMed Web of Science ®Google Scholar
• Besarab A, Ross R P, Nasca T J. The use of recombinant human erythropoietin in predialysis patients. Curr Opin Nephrol Hypertens 1995; 4: 155–161
   PubMedGoogle Scholar
• Obrador G T, Ruthazer R, Arora P, Kausz A T, Pereira B J. Prevalence of and factors associated with suboptimal care before initiation of dialysis in the United States. J Am Soc Nephrol 1999; 10: 1793–1800
   PubMed Web of Science ®Google Scholar
• Ismail N. Hemodialysis in the elderly. UpToDate 2006, Accessed at: http://www.utdol.com/utd/content/topic.do?topicKey=dialysis/19941&type=A&selectedTitle=25∼289. Accessed 20.7.2006
   Google Scholar
• Loos C, Briancon S, Frimat L, Hanesse B, Kessler M. Effect of end-stage renal disease on the quality of life of older patients. J Am Geriatr Soc 2003; 51: 229–233
   PubMed Web of Science ®Google Scholar
• Abrass C K. Renal disease in the elderly. Best Practice of Medicine 1999, Accessed at: http://merck2.micromedex.com/index.asp?page=bpm_cited&article_id=CPM01NP277. Accessed 31.1.2006
   Google Scholar
• Huisman R M. The deadly risk of late referral. Nephrol Dial Transplant 2004; 19: 2175–2180
   PubMed Web of Science ®Google Scholar
• O'Riordan S. Chronic kidney disease and older people – implications of the publication of the Part 2 of the National Service Framework for Renal Services. Age Ageing 2005; 34: 546–548
   PubMed Web of Science ®Google Scholar
• Epstein M. Aging and the kidney. J Am Soc Nephrol 1996; 7: 1106–1122
   PubMed Web of Science ®Google Scholar
• Choudhury D, Raj D SC, Levi M. Effect of aging on renal function and disease. The kidney7th ed, Brenner, Rector's. PA Saunders, Philadelphia 2004; 2305–2321
   Google Scholar
• Takazakura E, Sawabu N, Handa A, Takada A, Shinoda A, Takeuchi J. Intrarenal vascular changes with age and disease. Kidney Int 1972; 2: 224–230
   PubMed Web of Science ®Google Scholar
• Davison A M. Renal disease in the elderly. Nephron 1998; 80: 6–16
   PubMed Web of Science ®Google Scholar
• Lindeman R D, Tobin J, Shock N W. Longitudinal studies on the rate of decline in renal function with age. J Am Geriatr Soc 1985; 33: 278–285
   PubMed Web of Science ®Google Scholar
• Godin M, Moulin B, Etienne I, Fillastre J P. [Renal aging in man]. Presse Med 1992; 21: 1246–1248
   PubMed Web of Science ®Google Scholar
• Macias Nunez J F, Garcia I C, Bondia R A, Rodriguez Commes J L, Corbacho B L, Tabernero Romo J M, et al. Renal handling of sodium in old people: a functional study. Age Ageing 1978; 7: 178–181
   PubMedGoogle Scholar
• Luft F C, Fineberg N S, Miller J Z, Rankin L I, Grim C E, Weinberger M H. The effects of age, race and heredity on glomerular filtration rate following volume expansion and contraction in normal man. Am J Med Sci 1980; 279: 15–24
   PubMed Web of Science ®Google Scholar
• Fliser D, Zeier M, Nowack R, Ritz E. Renal functional reserve in healthy elderly subjects. J Am Soc Nephrol 1993; 3: 1371–1377
   PubMed Web of Science ®Google Scholar
• MacGregor M S, Boag D E, Innes A. Chronic kidney disease: evolving strategies for detection and management of impaired renal function. QJM 2006; 99: 365–375
   PubMed Web of Science ®Google Scholar
• NKF-K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification. 2002, 2006, Accessed at: http://www.kidney.org/professionals/KDOQI/guidelines_ckd/toc.htm
   Google Scholar
• Hall P M. Proteinuria, The Cleveland Clinic. Center for Continuing Education.Accessed at: http://www.clevelandclinicmeded.com/diseasemanagement/nephrology/proteinuria/proteinuria.htm. Accessed 20.8.2006
   Google Scholar
• K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification. Part 4. Definition and Classification of Stages of Chronic Kidney Disease, Accessed at: http://www.kidney.org/professionals/KDOQI/guidelines_ckd/p4_class_g1.htm. Accessed 11.3.2006
   Google Scholar
• Stevens L A, Levey A S. Clinical implications of estimating equations for glomerular filtration rate. Ann Intern Med 2004; 141: 959–961
   PubMed Web of Science ®Google Scholar
• Kelleher C L, Lindeman R D. Kidney Diseases and Disorders (chapter 50). Geriatrics review syllabus: a core curriculum in geriatric medicinesixth edition, P Pompei, J B Murphy. American Geriatrics Society, New York, NY 2006
   Google Scholar
• Stevens L, Perrone D R. Assessment of kidney function: serum creatinine; BUN; and GFR. UpToDate 2006, Version 14.3.Accessed at: http://www.utdol.com/utd/content/topic.do?topicKey=fldlytes/32110&type=A&selectedTitle=1∼30. Accessed 10.12.2006
   Google Scholar
• O'Riordan S E, Webb M C, Stowe H J, Simpson D E, Kandarpa M, Coakley A J, et al. Cystatin C improves the detection of mild renal dysfunction in older patients. Ann Clin Biochem 2003; 40: 648–655
   PubMed Web of Science ®Google Scholar
• Swedko P J, Clark H D, Paramsothy K, Akbari A. Serum creatinine is an inadequate screening test for renal failure in elderly patients. Arch Intern Med 2003; 163: 356–360
   PubMed Web of Science ®Google Scholar
• Fraser C G. Test result variation and the quality of evidence-based clinical guidelines. Clin Chim Acta 2004; 346: 19–24
   PubMed Web of Science ®Google Scholar
• Mussap M, Plebani M. Biochemistry and clinical role of human cystatin C. Crit Rev Clin Lab Sci 2004; 41: 467–550
   PubMed Web of Science ®Google Scholar
• Stevens L A, Levey A S. Chronic kidney disease in the elderly – how to assess risk. N Engl J Med 2005; 352: 2122–2124
   PubMed Web of Science ®Google Scholar
• Shlipak M G, Katz R, Sarnak M J, Fried L F, Newman A B, Stehman-Breen C, et al. Cystatin C and prognosis for cardiovascular and kidney outcomes in elderly persons without chronic kidney disease. Ann Intern Med 2006; 145: 237–246
   PubMed Web of Science ®Google Scholar
• Hoek F J, Kemperman F A, Krediet R T. A comparison between cystatin C, plasma creatinine and the Cockcroft and Gault formula for the estimation of glomerular filtration rate. Nephrol Dial Transplant 2003; 18: 2024–2031
   PubMed Web of Science ®Google Scholar
• Newman D J, Thakkar H, Edwards R G, Wilkie M, White T, Grubb A O, et al. Serum cystatin C measured by automated immunoassay: a more sensitive marker of changes in GFR than serum creatinine. Kidney Int 1995; 47: 312–318
   PubMed Web of Science ®Google Scholar
• Shlipak M G, Sarnak M J, Katz R, Fried L F, Seliger S L, Newman A B, et al. Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med 2005; 352: 2049–2060
   PubMed Web of Science ®Google Scholar
• Fricker M, Wiesli P, Brandle M, Schwegler B, Schmid C. Impact of thyroid dysfunction on serum cystatin C. Kidney Int 2003; 63: 1944–1947
   PubMed Web of Science ®Google Scholar
• Jayagopal V, Keevil B G, Atkin S L, Jennings P E, Kilpatrick E S. Paradoxical changes in cystatin C and serum creatinine in patients with hypo- and hyperthyroidism. Clin Chem 2003; 49: 680–681
   PubMed Web of Science ®Google Scholar
• Wiesli P, Schwegler B, Spinas G A, Schmid C. Serum cystatin C is sensitive to small changes in thyroid function. Clin Chim Acta 2003; 338: 87–90
   PubMed Web of Science ®Google Scholar
• Wasen E, Isoaho R, Mattila K, Vahlberg T, Kivela S L, Irjala K. Serum cystatin C in the aged: relationships with health status. Am J Kidney Dis 2003; 42: 36–43
   PubMed Web of Science ®Google Scholar
• Knight E L, Verhave J C, Spiegelman D, Hillege H L, de Z D, Curhan G C, et al. Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement. Kidney Int 2004; 65: 1416–1421
   PubMed Web of Science ®Google Scholar
• Macdonald J, Marcora S, Jibani M, Roberts G, Kumwenda M, Glover R, et al. GFR estimation using cystatin C is not independent of body composition. Am J Kidney Dis 2006; 48: 712–719
   PubMed Web of Science ®Google Scholar
• Coresh J, Astor B. Decreased kidney function in the elderly: clinical and preclinical, neither benign. Ann Intern Med 2006; 145: 299–301
   PubMed Web of Science ®Google Scholar
• Macisaac R J, Tsalamandris C, Thomas M C, Premaratne E, Panagiotopoulos S, Smith T J, et al. Estimating glomerular filtration rate in diabetes: a comparison of cystatin-C- and creatinine-based methods. Diabetologia 2006; 49: 1686–1689
   PubMed Web of Science ®Google Scholar
• Pedone C, Corsonello A, Incalzi R A. Estimating renal function in older people: a comparison of three formulas. Age Ageing 2006; 35: 121–126
   PubMed Web of Science ®Google Scholar
• Levey A S, Bosch J P, Lewis J B, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461–470
   PubMed Web of Science ®Google Scholar
• Levey A S, Bosch J P, Lewis J B, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461–470
   PubMed Web of Science ®Google Scholar
• Levin A. The advantage of a uniform terminology and staging system for chronic kidney disease (CKD). Nephrol Dial Transplant 2003; 18: 1446–1451
   PubMed Web of Science ®Google Scholar
• Kidney Health Australia. National Chronic Kidney Disease Strategy, Accessed at: http://www.kidney.org.au/?section=86&subsection=544. Accessed 28.8.2006
   Google Scholar
• Bertolatus J A, Goddard L. Evaluation of renal function in potential living kidney donors. Transplantation 2001; 71: 256–260
   PubMed Web of Science ®Google Scholar
• Bostom A G, Kronenberg F, Ritz E. Predictive performance of renal function equations for patients with chronic kidney disease and normal serum creatinine levels. J Am Soc Nephrol 2002; 13: 2140–2144
   PubMed Web of Science ®Google Scholar
• Kuan Y, Hossain M, Surman J, El Nahas A M, Haylor J. GFR prediction using the MDRD and Cockcroft and Gault equations in patients with end-stage renal disease. Nephrol Dial Transplant 2005; 20: 2394–2401
   PubMed Web of Science ®Google Scholar
• Lin J, Knight E L, Hogan M L, Singh A K. A comparison of prediction equations for estimating glomerular filtration rate in adults without kidney disease. J Am Soc Nephrol 2003; 14: 2573–2580
   PubMed Web of Science ®Google Scholar
• Pierrat A, Gravier E, Saunders C, Caira M V, it-Djafer Z, Legras B, et al. Predicting GFR in children and adults: a comparison of the Cockcroft-Gault, Schwartz, and modification of diet in renal disease formulas. Kidney Int 2003; 64: 1425–1436
   PubMed Web of Science ®Google Scholar
• Poggio E D, Wang X, Greene T, Van L F, Hall P M. Performance of the modification of diet in renal disease and Cockcroft-Gault equations in the estimation of GFR in health and in chronic kidney disease. J Am Soc Nephrol 2005; 16: 459–466
   PubMed Web of Science ®Google Scholar
• Rule A D, Larson T S, Bergstralh E J, Slezak J M, Jacobsen S J, Cosio F G. Using serum creatinine to estimate glomerular filtration rate: accuracy in good health and in chronic kidney disease. Ann Intern Med 2004; 141: 929–937
   PubMed Web of Science ®Google Scholar
• Rule A D, Gussak H M, Pond G R, Bergstralh E J, Stegall M D, Cosio F G, Larson T S. Measured and estimated GFR in healthy potential kidney donors. Am J Kidney Dis 2004; 43: 112–119
   PubMed Web of Science ®Google Scholar
• Stoves J, Lindley E J, Barnfield M C, Burniston M T, Newstead C G. MDRD equation estimates of glomerular filtration rate in potential living kidney donors and renal transplant recipients with impaired graft function. Nephrol Dial Transplant 2002; 17: 2036–2037
   PubMed Web of Science ®Google Scholar
• Vervoort G, Willems H L, Wetzels J F. Assessment of glomerular filtration rate in healthy subjects and normoalbuminuric diabetic patients: validity of a new (MDRD) prediction equation. Nephrol Dial Transplant 2002; 17: 1909–1913
   PubMed Web of Science ®Google Scholar
• Van Den Noortgate N J, Janssens W H, Delanghe J R, Afschrift M B, Lameire N H. Serum cystatin C concentration compared with other markers of glomerular filtration rate in the old old. J Am Geriatr Soc 2002; 50: 1278–1282
   PubMed Web of Science ®Google Scholar
• Lamb E J, Webb M C, Simpson D E, Coakley A J, Newman D J, O'Riordan S E. Estimation of glomerular filtration rate in older patients with chronic renal insufficiency: is the modification of diet in renal disease formula an improvement?. J Am Geriatr Soc 2003; 51: 1012–1017
   PubMed Web of Science ®Google Scholar
• Fehrman-Ekholm I, Skeppholm L. Renal function in the elderly (>70 years old) measured by means of iohexol clearance, serum creatinine, serum urea and estimated clearance. Scand J Urol Nephrol 2004; 38: 73–77
   PubMed Web of Science ®Google Scholar
• Clase C M, Garg A X, Kiberd B A. Classifying kidney problems: can we avoid framing risks as diseases?. BMJ 2004; 329: 912–915
   PubMedGoogle Scholar
• Haas M, Spargo B H, Wit E J, Meehan S M. Etiologies and outcome of acute renal insufficiency in older adults: a renal biopsy study of 259 cases. Am J Kidney Dis 2000; 35: 433–447
   PubMed Web of Science ®Google Scholar
• Modesto-Segonds A, Ah-Soune M F, Durand D, Suc J M. Renal biopsy in the elderly. Am J Nephrol 1993; 13: 27–34
   PubMed Web of Science ®Google Scholar
• Preston R A, Stemmer C L, Materson B J, Perez-Stable E, Pardo V. Renal biopsy in patients 65 years of age or older. An analysis of the results of 334 biopsies. J Am Geriatr Soc 1990; 38: 669–674
   PubMed Web of Science ®Google Scholar
• Pharmacological therapy: use of antihypertensives in CKD. K/DOQI Clinical Practice Guidelines on Hypertension and Antihypertensive Agents in Chronic Kidney Disease, Accessed at: http://www.kidney.org/professionals/KDOQI/guidelines_bp/guide_7.htm. Accessed 10.12.2006
   Google Scholar
• Use of diuretics in CKD. K/DOQI Clinical Practice Guidelines on Hypertension and Antihypertensive Agents in Chronic Kidney Disease, Accessed at: http://www.kidney.org/professionals/KDOQI/guidelines_bp/guide_12.htm. Accessed 10.12.2006
   Google Scholar
• Use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in CKD. K/DOQI Clinical Practice Guidelines on Hypertension and Antihypertensive Agents in Chronic Kidney Disease, Accessed at: http://www.kidney.org/professionals/KDOQI/guidelines_bp/guide_11.htm. Accessed 9.12.2006
   Google Scholar
• Bakris G L. Effects of diltiazem or lisinopril on massive proteinuria associated with diabetes mellitus. Ann Intern Med 1990; 112: 707–708
   PubMed Web of Science ®Google Scholar
• Bakris G L, Barnhill B W, Sadler R. Treatment of arterial hypertension in diabetic humans: importance of therapeutic selection. Kidney Int 1992; 41: 912–919
   PubMed Web of Science ®Google Scholar
• Bakris G L, Copley J B, Vicknair N, Sadler R, Leurgans S. Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy. Kidney Int 1996; 50: 1641–1650
   PubMed Web of Science ®Google Scholar
• Bohlen L, de Court Weidmann P. Comparative study of the effect of ACE-inhibitors and other antihypertensive agents on proteinuria in diabetic patients. Am J Hypertens 1994; 7: 84S–92S
   PubMed Web of Science ®Google Scholar
• Bakris G L, Weir M R, DeQuattro V, McMahon F G. Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy. Kidney Int 1998; 54: 1283–1289
   PubMed Web of Science ®Google Scholar
• Ritz E, Koch M. Morbidity and mortality due to hypertension in patients with renal failure. Am J Kidney Dis 1993; 21: 113–1118
   PubMed Web of Science ®Google Scholar
• Pharmacological therapy: diabetic kidney disease. K/DOQI Clinical Practice Guidelines on Hypertension and Antihypertensive Agents in Chronic Kidney Disease, Accessed at: http://www.kidney.org/professionals/KDOQI/guidelines_bp/guide_8.htm. Accessed 9.12.2006
   Google Scholar
• Pharmacological therapy: nondiabetic kidney disease. K/DOQI Clinical Practice Guidelines on Hypertension and Antihypertensive Agents in Chronic Kidney Disease, Accessed at: http://www.kidney.org/professionals/KDOQI/guidelines_bp/guide_9.htm. Accessed 9.12.2006
   Google Scholar
• Association of chronic kidney disease with diabetic complications. K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification, Accessed at: http://www.kidney.org/professionals/KDOQI/guidelines_ckd/p7_risk_g14.htm. Accessed 9.12.2006
   Google Scholar
• Deckert T, Kofoed-Enevoldsen A, Norgaard K, Borch-Johnsen K, Feldt-Rasmussen B, Jensen T. Microalbuminuria. Implications for micro- and macrovascular disease. Diabetes Care 1992; 15: 1181–1191
   PubMed Web of Science ®Google Scholar
• Perna A, Remuzzi G. Abnormal permeability to proteins and glomerular lesions: a meta-analysis of experimental and human studies. Am J Kidney Dis 1996; 27: 34–41
   PubMed Web of Science ®Google Scholar
• Diabetes. K/DOQI Clinical Practice Guidelines for Cardiovascular Disease in Dialysis Patients, Accessed at: http://www.kidney.org/professionals/KDOQI/guidelines_cvd/guide11.htm. Accessed 9.12.2006
   Google Scholar
• Borch-Johnsen K, Andersen P K, Deckert T. The effect of proteinuria on relative mortality in type 1 (insulin-dependent) diabetes mellitus. Diabetologia 1985; 28: 590–596
   PubMed Web of Science ®Google Scholar
• Nelson R G, Pettitt D J, Carraher M J, Baird H R, Knowler W C. Effect of proteinuria on mortality in NIDDM. Diabetes 1988; 37: 1499–1504
   PubMed Web of Science ®Google Scholar
• Joy M S, Cefalu W T, Hogan S L, Nachman P H. Long-term glycemic control measurements in diabetic patients receiving hemodialysis. Am J Kidney Dis 2002; 39: 297–307
   PubMed Web of Science ®Google Scholar
• Oyibo S O, Pritchard G M, McLay L, James E, Laing I, Gokal R, et al. Blood glucose overestimation in diabetic patients on continuous ambulatory peritoneal dialysis for end-stage renal disease. Diabet Med 2002; 19: 693–696
   PubMed Web of Science ®Google Scholar
• Tzamaloukas A H. Interpreting glycosylated hemoglobin in diabetic patients on peritoneal dialysis. Adv Perit Dial. 1996; 12: 171–175
   PubMedGoogle Scholar
• Association of chronic kidney disease with cardiovascular disease. K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification, Accessed at: http://www.kidney.org/professionals/KDOQI/guidelines_ckd/p7_risk_g15.htm. Accessed 9.12.2006
   Google Scholar
• Sarnak M J, Levey A S. Cardiovascular disease and chronic renal disease: a new paradigm. Am J Kidney Dis 2000; 35: S117–S131
   PubMed Web of Science ®Google Scholar
• Foley R N, Parfrey P S, Sarnak M J. Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol 1998; 9: S16–S23
   PubMed Web of Science ®Google Scholar
• Zager P G, Nikolic J, Brown R H, Campbell M A, Hunt W C, Peterson D, et al. ‘U’ curve association of blood pressure and mortality in hemodialysis patients. Medical Directors of Dialysis Clinic, Inc. Kidney Int. 1998; 54: 561–569
   Google Scholar
• Salahudeen A K. Obesity and survival on dialysis. Am J Kidney Dis 2003; 41: 925–932
   PubMed Web of Science ®Google Scholar
• Nishizawa Y, Shoji T, Ishimura E, Inaba M, Morii H. Paradox of risk factors for cardiovascular mortality in uremia: is a higher cholesterol level better for atherosclerosis in uremia?. Am J Kidney Dis 2001; 38: S4–S7
   Web of Science ®Google Scholar
• Kalantar-Zadeh K, Block G, Humphreys M H, Kopple J D. Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int 2003; 63: 793–808
   PubMed Web of Science ®Google Scholar
• Stevens J, Cai J, Pamuk E R, Williamson D F, Thun M J, Wood J L. The effect of age on the association between body-mass index and mortality. N Engl J Med 1998; 338: 1–7
   PubMed Web of Science ®Google Scholar
• Yeh S, Wu S Y, Levine D M, Parker T S, Olson J S, Stevens M R, et al. Quality of life and stimulation of weight gain after treatment with megestrol acetate: correlation between cytokine levels and nutritional status, appetite in geriatric patients with wasting syndrome. J Nutr Health Aging 2000; 4: 246–251
   PubMedGoogle Scholar
• Liu Y, Coresh J, Eustace J A, Longenecker J C, Jaar B, Fink N E, et al. Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition. JAMA 2004; 291: 451–459
   PubMed Web of Science ®Google Scholar
• Kalantar-Zadeh K. Recent advances in understanding the malnutrition-inflammation-cachexia syndrome in chronic kidney disease patients: what is next?. Semin Dial 2005; 18: 365–369
   PubMed Web of Science ®Google Scholar
• Kalantar-Zadeh K, Block G, McAllister C J, Humphreys M H, Kopple J D. Appetite and inflammation, nutrition, anemia, and clinical outcome in hemodialysis patients. Am J Clin Nutr 2004; 80: 299–307
   PubMed Web of Science ®Google Scholar
• Stenvinkel P, Heimburger O, Lindholm B. Wasting, but not malnutrition, predicts cardiovascular mortality in end-stage renal disease. Nephrol Dial Transplant 2004; 19: 2181–2183
   PubMed Web of Science ®Google Scholar
• Stenvinkel P, Pecoits-Filho R, Lindholm B. Coronary artery disease in end-stage renal disease: no longer a simple plumbing problem. J Am Soc Nephrol 2003; 14: 1927–1939
   PubMed Web of Science ®Google Scholar
• Blood pressure. K/DOQI Clinical Practice Guidelines for Cardiovascular Disease in Dialysis Patients, Accessed at: http://www.kidney.org/professionals/KDOQI/guidelines_cvd/guide12.htm. Accessed 9.12.2006
   Google Scholar
• Hsu C Y, McCulloch C E, Curhan G C. Epidemiology of anemia associated with chronic renal insufficiency among adults in the United States: results from the Third National Health and Nutrition Examination Survey. J Am Soc Nephrol 2002; 13: 504–510
   PubMed Web of Science ®Google Scholar
• Braumann K M, Nonnast-Daniel B, Boning D, Bocker A, Frei U. Improved physical performance after treatment of renal anemia with recombinant human erythropoietin. Nephron 1991; 58: 129–134
   PubMed Web of Science ®Google Scholar
• Cannella G, La C G, Sandrini M, Gaggiotti M, Nordio G, Movilli E, et al. Renormalization of high cardiac output and of left ventricular size following long-term recombinant human erythropoietin treatment of anemic dialyzed uremic patients. Clin Nephrol 1990; 34: 272–278
   PubMed Web of Science ®Google Scholar
• Gafter U, Kalechman Y, Orlin J B, Levi J, Sredni B. Anemia of uremia is associated with reduced in vitro cytokine secretion: immunopotentiating activity of red blood cells. Kidney Int 1994; 45: 224–231
   PubMed Web of Science ®Google Scholar
• Harnett J D, Foley R N, Kent G M, Barre P E, Murray D, Parfrey P S. Congestive heart failure in dialysis patients: prevalence, incidence, prognosis and risk factors. Kidney Int 1995; 47: 884–890
   PubMed Web of Science ®Google Scholar
• Horina J H, Schwaberger G, Brussee H, Sauseng-Fellegger G, Holzer H, Krejs G J. Increased red cell 2,3-diphosphoglycerate levels in haemodialysis patients treated with erythropoietin. Nephrol Dial Transplant 1993; 8: 1219–1222
   PubMed Web of Science ®Google Scholar
• Macdougall I C, Lewis N P, Saunders M J, Cochlin D L, Davies M E, Hutton R D, et al. Long-term cardiorespiratory effects of amelioration of renal anaemia by erythropoietin. Lancet 1990; 335: 489–493
   PubMed Web of Science ®Google Scholar
• Mayer G, Thum J, Cada E M, Stummvoll H K, Graf H. Working capacity is increased following recombinant human erythropoietin treatment. Kidney Int 1988; 34: 525–528
   PubMed Web of Science ®Google Scholar
• Pascual J, Teruel J L, Moya J L, Liano F, Jimenez-Mena M, Ortuno J. Regression of left ventricular hypertrophy after partial correction of anemia with erythropoietin in patients on hemodialysis: a prospective study. Clin Nephrol 1991; 35: 280–287
   PubMed Web of Science ®Google Scholar
• Robertson H T, Haley N R, Guthrie M, Cardenas D, Eschbach J W, Adamson J W. Recombinant erythropoietin improves exercise capacity in anemic hemodialysis patients. Am J Kidney Dis 1990; 15: 325–332
   PubMed Web of Science ®Google Scholar
• Sobh M A, Abd eH I, Atta M G, Refaie A F. Effect of erythropoietin on sexual potency in chronic haemodialysis patients. A preliminary study. Scand J Urol Nephrol 1992; 26: 181–185
   PubMed Web of Science ®Google Scholar
• Teehan B, Sigler M H, Brown J M, Benz R L, Gilgore G S, Schleifer C R, et al. Hematologic and physiologic studies during correction of anemia with recombinant human erythropoietin in predialysis patients. Transplant Proc 1989; 212: 63–69
   Google Scholar
• Vanholder R, Van B W, Ringoir S. Contributing factors to the inhibition of phagocytosis in hemodialyzed patients. Kidney Int 1993; 44: 208–214
   PubMed Web of Science ®Google Scholar
• Wizemann V, Kaufmann J, Kramer W. Effect of erythropoietin on ischemia tolerance in anemic hemodialysis patients with confirmed coronary artery disease. Nephron 1992; 62: 161–165
   PubMed Web of Science ®Google Scholar
• Wizemann V, Schafer R, Kramer W. Follow-up of cardiac changes induced by anemia compensation in normotensive hemodialysis patients with left-ventricular hypertrophy. Nephron 1993; 64: 202–206
   PubMed Web of Science ®Google Scholar
• Wolcott D L, Marsh J T, La R A, Carr C, Nissenson A R. Recombinant human erythropoietin treatment may improve quality of life and cognitive function in chronic hemodialysis patients. Am J Kidney Dis 1989; 14: 478–485
   PubMed Web of Science ®Google Scholar
• Factors associated with loss of kidney function in chronic kidney disease. K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification, Accessed at: http://www.kidney.org/professionals/kdoqi/guidelines_ckd/p7_risk_g13.htm. Accessed 9.12.2006
   Google Scholar
• Morbidity and mortality of renal dialysis: an NIH consensus conference statement. Consensus Development Conference Panel. Ann Intern Med 1994; 121: 62–70
   PubMed Web of Science ®Google Scholar
• NKF-K/DOQI Clinical practice guidelines for anemia of chronic kidney disease: update 2000. Am J Kidney Dis 2001; 37: S182–S238
   PubMed Web of Science ®Google Scholar
• Evans R W, Rader B, Manninen D L. The quality of life of hemodialysis recipients treated with recombinant human erythropoietin. Cooperative Multicenter EPO Clinical Trial Group. JAMA 1990; 263: 825–830
   PubMed Web of Science ®Google Scholar
• Grutzmacher P, Scheuermann E, Low I, Bergmann M, Rauber K, Baum R, et al. Correction of renal anaemia by recombinant human erythropoietin: effects on myocardial function. Contrib Nephrol 1988; 66: 176–184
   PubMedGoogle Scholar
• Lowrie E G, Ling J, Lew N L, Yiu Y. The relative contribution of measured variables to death risk among hemodialysis patients. Death on hemodialysis: preventable or inevitable?, E A Friedman. Kluwer Academic Publishers, Boston, MA 1994; 121–141
   Google Scholar
• Mocks J, Frank W, Ehmer B, Scigalla P, Quarder O. Analysis of safety database for long-term epoetin-beta treatment. A meta-analysis covering 3697 patients. Pathogenetic and therapeutic aspects of chronic renal failure, K M Koch, G Stein. Marcel Dekker, New York 1997; 163–179
   Google Scholar
• Renal Physicians Association: Appropriate Preparation of the Patient for Renal Replacement Therapy: Clinical Practice Guideline No. 3. RPA, Rockville, MD 2002
   Google Scholar
• Collins A J, Li S, Ebben J, Ma J Z, Manning W. Hematocrit levels and associated Medicare expenditures. Am J Kidney Dis 2000; 36: 282–293
   PubMed Web of Science ®Google Scholar
• Collins A J, Li S, St P W, Ebben J, Roberts T, Ma J Z, et al. Death, hospitalization, and economic associations among incident hemodialysis patients with hematocrit values of 36 to 39%. J Am Soc Nephrol 2001; 12: 2465–2473
   PubMed Web of Science ®Google Scholar
• Fink J, Blahut S, Reddy M, Light P. Use of erythropoietin before the initiation of dialysis and its impact on mortality. Am J Kidney Dis 2001; 37: 348–355
   PubMed Web of Science ®Google Scholar
• Ma J Z, Ebben J, Xia H, Collins A J. Hematocrit level and associated mortality in hemodialysis patients. J Am Soc Nephrol 1999; 10: 610–619
   PubMed Web of Science ®Google Scholar
• Owen W F, Jr. Patterns of care for patients with chronic kidney disease in the United States: dying for improvement. J Am Soc Nephrol 2003; 14: S76–S80
   Web of Science ®Google Scholar
• US Renal Data System. USRDS 2002 Annual report: atlas of end-stage renal disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD 2002
   Google Scholar
• Owen W F, Jr., Szczech L, Johnson C, Frankenfield D. National perspective on iron therapy as a clinical performance measure for maintenance hemodialysis patients. Am J Kidney Dis 1999; 34: S5–S11
   PubMed Web of Science ®Google Scholar
• Nurko S. Anemia in chronic kidney disease: causes, diagnosis, treatment. Cleve Clin J Med 2006; 73: 289–297
   PubMed Web of Science ®Google Scholar
• Ganz T. Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood 2003; 102: 783–788
   PubMed Web of Science ®Google Scholar
• Moreno F, Sanz-Guajardo D, Lopez-Gomez J M, Jofre R, Valderrabano F. Increasing the hematocrit has a beneficial effect on quality of life and is safe in selected hemodialysis patients. Spanish Cooperative Renal Patients Quality of Life Study Group of the Spanish Society of Nephrology. J Am Soc Nephrol 2000; 11: 335–342
   PubMed Web of Science ®Google Scholar
• KDOQI. Clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis 2006; 47: S11–S145
   PubMed Web of Science ®Google Scholar
• Locatelli F, Aljama P, Barany P, Canaud B, Carrera F, Eckardt K U, et al. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 2004; 19(Suppl 2)ii1–47
   PubMedGoogle Scholar
• NKF-K/DOQI guidelines: anemia of chronic kidney disease: iron support. UpToDate 2006, Version 14.3. Accessed at: http://uptodateonline.com/utd/content/topic.do?topicKey=nkf_doqi/14137&type=A&selectedTitle=165∼333. Accessed 7.12.2006
   Google Scholar
• NKF-K/DOQI Clinical practice guidelines for anemia of chronic kidney disease: iron support: Update. 2000, Accessed at: http://www.kidney.org/professionals/kdoqi/guidelines/doqi_uptoc.html#an. Accessed 7.12.2006
   Google Scholar
• Drueke T B, Locatelli F, Clyne N, Eckardt K U, Macdougall I C, Tsakiris D, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006; 355: 2071–2084
   PubMed Web of Science ®Google Scholar
• Remuzzi G, Ingelfinger J R. Correction of anemia – payoffs and problems. N Engl J Med 2006; 355: 2144–2146
   PubMed Web of Science ®Google Scholar
• Singh A K, Szczech L, Tang K L, Barnhart H, Sapp S, Wolfson M, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006; 355: 2085–2098
   PubMed Web of Science ®Google Scholar
• Berns J S, Cronin R E, Henrich W L. Erythropoietin for the anemia of chronic kidney disease. UpToDate 2006, Version 14.3. Accessed at: http://www.utdol.com/utd/content/topic.do?topicKey=dialysis/9597&type=A&selectedTitle=18∼333. Accessed 9.1.2007
   Google Scholar
• Nissenson A R, Anand S. Darbepoetin alfa for the management of anemia in chronic kidney disease. UpToDate 2006, Version 14.3. Accessed at: http://uptodateonline.com/utd/content/topic.do?topicKey=dialysis/39273&type=A&selectedTitle=1∼17. Accessed 7.12.2006
   Google Scholar
• VHA/DoD Clinical practice guideline for management of chronic kidney disease and pre-ESRD in primary care setting, Accessed at: http://www.oqp.med.va.gov/cpg/ESRD/ESRD_cpg/algoframe.htm. Accessed 9.12.2006
   Google Scholar
• Muhlberg W, Platt D. Age-dependent changes of the kidneys: pharmacological implications. Gerontology 1999; 45: 243–253
   PubMed Web of Science ®Google Scholar
• Cantu T G, Ellerbeck E F, Yun S W, Castine S D, Kornhauser D M. Drug prescribing for patients with changing renal function. Am J Hosp Pharm 1992; 49: 2944–2948
   PubMedGoogle Scholar
• Canadian Institute for Health Information. Report, Volume 1: Dialysis and renal transplantation. Canadian organ replacement register. Canadian Institute for Health Information, Ottawa 2000
   Google Scholar
• Davison S N. Quality end-of-life care in dialysis units. Semin Dial 2002; 15: 41–44
   PubMed Web of Science ®Google Scholar
• Deoreo P B. Hemodialysis patient-assessed functional health status predicts continued survival, hospitalization, and dialysis-attendance compliance. Am J Kidney Dis 1997; 30: 204–212
   PubMed Web of Science ®Google Scholar
• Kimmel P L, Weihs K, Peterson R A. Survival in hemodialysis patients: the role of depression. J Am Soc Nephrol 1993; 4: 12–27
   PubMed Web of Science ®Google Scholar
• McClellan W M, Anson C, Birkeli K, Tuttle E. Functional status and quality of life: predictors of early mortality among patients entering treatment for end stage renal disease. J Clin Epidemiol 1991; 44: 83–89
   PubMed Web of Science ®Google Scholar
• McClellan W M, Stanwyck D J, Anson C A. Social support and subsequent mortality among patients with end-stage renal disease. J Am Soc Nephrol 1993; 4: 1028–1034
   PubMed Web of Science ®Google Scholar
• Parkerson G R, Jr, Broadhead W E, Tse C K. Health status and severity of illness as predictors of outcomes in primary care. Med Care 1995; 33: 53–66
   PubMed Web of Science ®Google Scholar
• Smith C, Da Silva-Gane M, Chandna S, Warwicker P, Greenwood R, Farrington K. Choosing not to dialyse: evaluation of planned non-dialytic management in a cohort of patients with end-stage renal failure. Nephron Clin Pract 2003; 95: c40–c46
   PubMed Web of Science ®Google Scholar
• Braveman C, Cohen L M. Discontinuation of dialysis: the role of hospice and palliative care. AAHPM Bull 2003; 3: 16–17
   Google Scholar
• Holley J L. A single-center review of the death notification form: discontinuing dialysis before death is not a surrogate for withdrawal from dialysis. Am J Kidney Dis 2002; 40: 525–530
   PubMed Web of Science ®Google Scholar
• Holley J L. Palliative care in end-stage renal disease: focus on advance care planning, hospice referral, and bereavement. Semin Dial 2005; 18: 154–156
   PubMed Web of Science ®Google Scholar
• Moss A H, Holley J L, Davison S N, Dart R A, Germain M J, Cohen L, et al. Palliative care. Am J Kidney Dis 2004; 43: 172–173
   PubMed Web of Science ®Google Scholar
• Fazekas G, Fazekas F, Schmidt R, Kapeller P, Offenbacher H, Krejs G J. Brain MRI findings and cognitive impairment in patients undergoing chronic hemodialysis treatment. J Neurol Sci 1995; 134: 83–88
   PubMed Web of Science ®Google Scholar
• Madan P, Kalra O P, Agarwal S, Tandon O P. Cognitive impairment in chronic kidney disease. Nephrol Dial Transplant 2006; 22: 440–444
   PubMedGoogle Scholar
• Sehgal A R, Grey S F, Deoreo P B, Whitehouse P J. Prevalence, recognition, and implications of mental impairment among hemodialysis patients. Am J Kidney Dis 1997; 30: 41–49
   PubMed Web of Science ®Google Scholar
• Kurella M, Chertow G M, Luan J, Yaffe K. Cognitive impairment in chronic kidney disease. J Am Geriatr Soc 2004; 52: 1863–1869
   PubMed Web of Science ®Google Scholar
• Kurella M, Bennett W M, Chertow G M. Analgesia in patients with ESRD: a review of available evidence. Am J Kidney Dis 2003; 42: 217–228
   PubMed Web of Science ®Google Scholar
• Griffin M R, Ray W A, Schaffner W. Nonsteroidal anti-inflammatory drug use and death from peptic ulcer in elderly persons. Ann Intern Med 1988; 109: 359–363
   PubMed Web of Science ®Google Scholar
• Griffin M R, Piper J M, Daugherty J R, Snowden M, Ray W A. Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons. Ann Intern Med 1991; 114: 257–263
   PubMed Web of Science ®Google Scholar
• Greenberger N J. Update in gastroenterology. Ann Intern Med 1997; 126: 221–225
   PubMed Web of Science ®Google Scholar
• Hawkey C J, Karrasch J A, Szczepanski L, Walker D G, Barkun A, Swannell A J. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus misoprostol for NSAID-induced ulcer management (OMNIUM) study group. N Engl J Med 1998; 338: 727–734
   PubMed Web of Science ®Google Scholar
• Yeomans N D, Tulassay Z, Juhasz L, Racz I, Howard J M, van Rensburg C J. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid suppression trial: ranitidine versus omeprazole for NSAID-associated ulcer treatment (ASTRONAUT) study group. N Engl J Med7 1998; 338: 719–726
   PubMed Web of Science ®Google Scholar